中西医结合治疗肝衰竭系统评价及愈肝解毒汤治疗肝损伤实验研究
|
摘要
研究目的：
在中医理论指导下,首先应用Meta分析评价中西医结合治疗肝衰竭是否有助于提高疗效,为中西医结合治疗肝衰竭的临床疗效作出较客观、可信的评价,并为临床治疗决策提供依据；其次探讨了愈肝解毒汤对D-氨基半乳糖及四氯化碳所致的急性肝损伤实验动物模型的治疗效果及作用机制。为中医治疗急性肝损伤提供真实、科学的依据。
研究方法：
关于Meta分析：严格按照循证医学系统评价的方法,采用电子和手工检索的方法,全面收集中西医结合治疗肝衰竭的临床随机对照试验(RCT)：并按照文献选择标准进行筛选；采用Jadad评分标准评价纳入研究的方法学质量；采集相关数据进行同质性检验及Meta-分析,并进行发表性偏倚分析及敏感性分析等。
实验研究：选择愈肝解毒汤对D-氨基半乳糖(D-Galactosamine, D-GalN)及四氯化碳(Carbon tetrachloride. CCL4)所致的急性肝损伤大鼠进行干预,检测生化、免疫、病理、细胞通路等指标.研究愈肝解毒汤治疗肝损伤大鼠的机制。
研究结果：
1.经文献检索及筛选,符合纳入标准的治疗肝衰竭的随机对照试验17篇,共1192例病人,17篇文献方法学质量均为C级。Meta分析显示对于治疗肝衰竭,中西医结合的治疗组临床有效率优于单纯西医综合治疗的对照组。
2.愈肝解毒汤对D-氨基半乳糖及四氯化碳所致急性肝损伤大鼠均有治疗作用。愈肝解毒汤高、中剂量组能够使升高的转氨酶、胆红素降低,改善凝血功能,与模型组相比有统计学意义(P<0.05),能够调节血浆中促炎因子肿瘤坏死因子-α (Tumor necrosis factor alpha.TNF-α)、白细胞介素-1(Interleukin-1,IL-1)、白细胞介素-6(Interleukin-6, IL-6)、白细胞介素-8(Interleukin-8,IL-8)的含量,使升高的促炎因子下降,并具有统计学意义(P<0.05)。.能改善急性肝损伤大鼠肝组织的病理变化,缩小病变面积,减轻肝细胞病变程度。愈肝解毒汤对D-氨基半乳糖所致急性肝损伤大鼠的核因子NF-KB(nuclear factor-kappa B, NF-κB)信号通路也有一定的影响。
结论
1.有中医干预的治疗组治疗肝衰竭临床有效率优于单纯西医综合治疗的对照组；但由于纳入文献的质量、研究方法等原因,中西医结合治疗肝衰竭的确切疗效尚有待于进一步证实,应设计更加严格的多中心、大样本随机对照实验。
2.中、高剂量愈肝解毒汤显著减轻D-氨基半乳糖及四氯化碳所致大鼠的肝细胞损伤,降低血浆中转氨酶和总胆红素的含量,具有较好的保肝降酶作用。同时在病理方面,二者能显著改善肝组织的病理变化,缩小病变的面积,减轻肝细胞损伤的程度。并可调节一系列促炎细胞因子,通过调节机体炎症反应而起到保肝的作用。愈肝解毒汤低剂量组也有一定的保肝降酶作用,但其各指标结果之间差异较大,效果较难评价。
3.愈肝解毒汤的高剂量组对D-氨基半乳糖所致急性肝损伤大鼠的核因子-KB信号转导通路也有一定的影响,可能通过调节细胞因子-细胞信号转导通路起到保肝的作用。
Objective:
Under the guidance of TCM theory, first applied Meta-analysis to evaluate integrative Medicine in the treatment of liver failure, to help improve efficacy for Integrative Medicine clinical efficacy for the treatment of liver failure, to make a more objective and credible evaluation, and provide the basis for clinical treatment decisions; Secondly, to explore the treatment effect and mechanism of the Yuganjiedu decoction on the D-galactosamine and carbon tetrachloride-induced acute liver injury in experimental animal models. To provide real scientific basis for the Chinese medicine treatment of acute liver injury.
Methods:
About the Meta-analysis:in strict accordance with the method of systematic reviews of evidence-based medicine, the use of electronic and manual search methods, a comprehensive collection of Integrative Medicine in the treatment of liver failure clinical randomized controlled trials (RCTs); and filter according to the literature selection criteria:using the Jadad scorecriteria to evaluate the methodological quality of included studies; to collect relevant data for the homogeneity test and meta-analysis, and publication bias and sensitivity analysis.
Experimental Study:Yuganjiedu decoction on D-galactosamine (D-GalN) and carbon tetrachloride (CCL4)-induced acute liver injury in rats, intervention, detection of biochemical, immunological, pathology, the cellular pathways and other indicators of research more liver detoxification treatment of liver injury in rats mechanisms.
Results:
The literature search and screening, met the inclusion criteria of randomized controlled trials of treatment of hepatic failure17, a total of1192patients,17were methodological treatment is C-class. Meta-analysis for the treatment of liver failure, medical intervention in the treatment group are more efficient than the simple TCM and Western medicine treatment control group.
Experimental Study:Yuganjiedu decoction on the D-galactosamine and carbon tetrachloride induced acute liver injury in rats have a therapeutic effect. Yuganjiedu decoction, the middle dose group elevated transaminases, bilirubin levels, improve blood coagulation, compared with model group was statistically significant(P<0.05), can regulate plasma proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha), interleukin prime-1(IL-1), white blood cells interleukin-6(IL-6), interleukin-8(1L-8) content, the elevated pro-inflammatory cytokines decreased, and was statistically significant (P<0.05). Can improve the pathological changes of acute liver injury in rat liver tissue bridging the lesion area, and reduce the severity of the liver cells. Yuganjiedu decoction on D-Amino galactose-induced acute liver injury in rats, the nuclear factor NF-kappa B (nuclear factor-kappa B) signaling pathway also have a certain impact.
Conclusion
(1) TCM intervention treatment group, liver failure clinical efficiency than pure TCM and Western medicine treatment control group; into the quality of literature, research methods, and other reasons, the exact effect of Integrative treatment of hepatic failure has yet to be confirmed, should be designed to more rigorous multi-center, randomized controlled trials.
(2) Yuganjiedu decoction of high dose to reduce the D-galactosamine and carbon tetrachloride induced rat liver cell injury, lower plasma transaminase and total bilirubin, with a protective drop enzyme. At the same time in the pathological aspects, the two can significantly improve the pathological changes of liver tissue, reduce the area of the lesion, reducing the degree of liver damage. Can regulate a series of pro-inflammatory cytokines play a hepatoprotective role by regulating the body's inflammatory response. More, Yuganjiedu decoction low-dose group there are certain the hepatoprotective JiangMei role, but the difference between the results of its indicators, the effect is difficult to evaluation.
Yuganjiedu decoction of high-dose group on D-Amino galactose-induced acute liver injury in rats, nuclear factor-KB signaling pathway also have a certain impact, possibly through modulation of cytokines-cell signal transduction pathways play a the hepatoprotective the role.
在中医理论指导下,首先应用Meta分析评价中西医结合治疗肝衰竭是否有助于提高疗效,为中西医结合治疗肝衰竭的临床疗效作出较客观、可信的评价,并为临床治疗决策提供依据；其次探讨了愈肝解毒汤对D-氨基半乳糖及四氯化碳所致的急性肝损伤实验动物模型的治疗效果及作用机制。为中医治疗急性肝损伤提供真实、科学的依据。
研究方法：
关于Meta分析：严格按照循证医学系统评价的方法,采用电子和手工检索的方法,全面收集中西医结合治疗肝衰竭的临床随机对照试验(RCT)：并按照文献选择标准进行筛选；采用Jadad评分标准评价纳入研究的方法学质量；采集相关数据进行同质性检验及Meta-分析,并进行发表性偏倚分析及敏感性分析等。
实验研究：选择愈肝解毒汤对D-氨基半乳糖(D-Galactosamine, D-GalN)及四氯化碳(Carbon tetrachloride. CCL4)所致的急性肝损伤大鼠进行干预,检测生化、免疫、病理、细胞通路等指标.研究愈肝解毒汤治疗肝损伤大鼠的机制。
研究结果：
1.经文献检索及筛选,符合纳入标准的治疗肝衰竭的随机对照试验17篇,共1192例病人,17篇文献方法学质量均为C级。Meta分析显示对于治疗肝衰竭,中西医结合的治疗组临床有效率优于单纯西医综合治疗的对照组。
2.愈肝解毒汤对D-氨基半乳糖及四氯化碳所致急性肝损伤大鼠均有治疗作用。愈肝解毒汤高、中剂量组能够使升高的转氨酶、胆红素降低,改善凝血功能,与模型组相比有统计学意义(P<0.05),能够调节血浆中促炎因子肿瘤坏死因子-α (Tumor necrosis factor alpha.TNF-α)、白细胞介素-1(Interleukin-1,IL-1)、白细胞介素-6(Interleukin-6, IL-6)、白细胞介素-8(Interleukin-8,IL-8)的含量,使升高的促炎因子下降,并具有统计学意义(P<0.05)。.能改善急性肝损伤大鼠肝组织的病理变化,缩小病变面积,减轻肝细胞病变程度。愈肝解毒汤对D-氨基半乳糖所致急性肝损伤大鼠的核因子NF-KB(nuclear factor-kappa B, NF-κB)信号通路也有一定的影响。
结论
1.有中医干预的治疗组治疗肝衰竭临床有效率优于单纯西医综合治疗的对照组；但由于纳入文献的质量、研究方法等原因,中西医结合治疗肝衰竭的确切疗效尚有待于进一步证实,应设计更加严格的多中心、大样本随机对照实验。
2.中、高剂量愈肝解毒汤显著减轻D-氨基半乳糖及四氯化碳所致大鼠的肝细胞损伤,降低血浆中转氨酶和总胆红素的含量,具有较好的保肝降酶作用。同时在病理方面,二者能显著改善肝组织的病理变化,缩小病变的面积,减轻肝细胞损伤的程度。并可调节一系列促炎细胞因子,通过调节机体炎症反应而起到保肝的作用。愈肝解毒汤低剂量组也有一定的保肝降酶作用,但其各指标结果之间差异较大,效果较难评价。
3.愈肝解毒汤的高剂量组对D-氨基半乳糖所致急性肝损伤大鼠的核因子-KB信号转导通路也有一定的影响,可能通过调节细胞因子-细胞信号转导通路起到保肝的作用。
Objective:
Under the guidance of TCM theory, first applied Meta-analysis to evaluate integrative Medicine in the treatment of liver failure, to help improve efficacy for Integrative Medicine clinical efficacy for the treatment of liver failure, to make a more objective and credible evaluation, and provide the basis for clinical treatment decisions; Secondly, to explore the treatment effect and mechanism of the Yuganjiedu decoction on the D-galactosamine and carbon tetrachloride-induced acute liver injury in experimental animal models. To provide real scientific basis for the Chinese medicine treatment of acute liver injury.
Methods:
About the Meta-analysis:in strict accordance with the method of systematic reviews of evidence-based medicine, the use of electronic and manual search methods, a comprehensive collection of Integrative Medicine in the treatment of liver failure clinical randomized controlled trials (RCTs); and filter according to the literature selection criteria:using the Jadad scorecriteria to evaluate the methodological quality of included studies; to collect relevant data for the homogeneity test and meta-analysis, and publication bias and sensitivity analysis.
Experimental Study:Yuganjiedu decoction on D-galactosamine (D-GalN) and carbon tetrachloride (CCL4)-induced acute liver injury in rats, intervention, detection of biochemical, immunological, pathology, the cellular pathways and other indicators of research more liver detoxification treatment of liver injury in rats mechanisms.
Results:
The literature search and screening, met the inclusion criteria of randomized controlled trials of treatment of hepatic failure17, a total of1192patients,17were methodological treatment is C-class. Meta-analysis for the treatment of liver failure, medical intervention in the treatment group are more efficient than the simple TCM and Western medicine treatment control group.
Experimental Study:Yuganjiedu decoction on the D-galactosamine and carbon tetrachloride induced acute liver injury in rats have a therapeutic effect. Yuganjiedu decoction, the middle dose group elevated transaminases, bilirubin levels, improve blood coagulation, compared with model group was statistically significant(P<0.05), can regulate plasma proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha), interleukin prime-1(IL-1), white blood cells interleukin-6(IL-6), interleukin-8(1L-8) content, the elevated pro-inflammatory cytokines decreased, and was statistically significant (P<0.05). Can improve the pathological changes of acute liver injury in rat liver tissue bridging the lesion area, and reduce the severity of the liver cells. Yuganjiedu decoction on D-Amino galactose-induced acute liver injury in rats, the nuclear factor NF-kappa B (nuclear factor-kappa B) signaling pathway also have a certain impact.
Conclusion
(1) TCM intervention treatment group, liver failure clinical efficiency than pure TCM and Western medicine treatment control group; into the quality of literature, research methods, and other reasons, the exact effect of Integrative treatment of hepatic failure has yet to be confirmed, should be designed to more rigorous multi-center, randomized controlled trials.
(2) Yuganjiedu decoction of high dose to reduce the D-galactosamine and carbon tetrachloride induced rat liver cell injury, lower plasma transaminase and total bilirubin, with a protective drop enzyme. At the same time in the pathological aspects, the two can significantly improve the pathological changes of liver tissue, reduce the area of the lesion, reducing the degree of liver damage. Can regulate a series of pro-inflammatory cytokines play a hepatoprotective role by regulating the body's inflammatory response. More, Yuganjiedu decoction low-dose group there are certain the hepatoprotective JiangMei role, but the difference between the results of its indicators, the effect is difficult to evaluation.
Yuganjiedu decoction of high-dose group on D-Amino galactose-induced acute liver injury in rats, nuclear factor-KB signaling pathway also have a certain impact, possibly through modulation of cytokines-cell signal transduction pathways play a the hepatoprotective the role.
引文
[1]Polson J, Lee WM. AASLD position paper:the management of acute liver failure [J]. Hepatology,2005,41 (5):1179-1197
[2]中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南[J].中华传染病杂志,2006,24(6)：422-425
[3]中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南[J].国际流行病学传染病学杂志,2006,33(4)：217-221
[4]郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社,2002.143-151
[5]Jadad AR, Moore A, Carroll D, etal. Assessing the quality of reports of randomized clinical trials:Is blinding necessary[J].Control Clin TriMs,1996,17:1-12
[6]黄裕红,谌宁生,阳航等.解毒化瘀汤联合中药保留灌肠治疗肝衰竭临床观察[.J].中国中医急证,2007,16(11)：1336-1337
[7]黄裕红,谌宁生,肖俊.中西医结合治疗肝衰竭36例[J].中医研究,2007,20(9)：24-25
[8]谢冬梅,何俊毅姚,立红等.肝衰合剂保留灌肠治疗肝衰竭21例临床观察[J].浙江中医杂志,2008,43(1)：34-35
[9]李建阳,张庭澍,罗蓬等.加味大承气汤灌肠治疗肝衰竭102例[J].陕西中医,2008,29(12)：1639-1640
[10]徐霞,陈飞,谢冬梅.大黄赤芍汤保留灌肠治疗肝衰竭的效果观察[J].护理与康复,2009,8(7)：616-617
[11]刘炜.中西医结合治疗重型肝炎湿热内蕴证疗效观察[J].湖北中医杂志,2009,31(1)：20-21
[12]孙元鹏.中西医结合治疗重症肝炎临床疗效观察[J].山西中医,2009,25(9)：29-30
[13]张鹏程.茵陈五苓散加减治疗肝衰竭的理论与临床研究[D].南京中医药大学
[14]毛建华.加味茵陈蒿汤合加减大承气汤治疗慢性重症肝炎临床疗效观察.医 学信息.2010,7：1954-1955
[15]刘政芳,潘晨,张元芬等.中西医结合治疗慢性乙型肝炎肝衰竭的临床研究.传染病信息,2010,23(5)：287-290
[16]陈全超.中西医结合治疗重症肝炎30例临床分析.亚太传统医药,2010,6(7)：42-43
[17]陈飞,徐洁,谢冬梅等.二黄解毒汤保留灌肠治疗肝功能衰竭的疗效观察及护理[J].海峡药学,2010,22(2)：121-123
[18]谢冬梅,程志文,何俊毅.肝病8号方灌肠治疗肝衰竭59例[J].江西中医药,2010,41(328)：31-32
[19]胡建华,钱英,姚乃礼.“截断逆挽法”治疗慢性乙型重型肝炎临床疗效观察[J].中西医结合肝病杂志,2010,20(4)：200-204
[20]徒康宛.清热解毒-活血化瘀-益气养阴法治疗肝衰竭内毒素血症的研究[D].南京中医药大学
[21]张强.79例亚急性肝衰竭患者临床特征分析及中西医结合治疗疗效评价[D].北京中医药大学
[22]沈云.慢加急性肝衰竭临床特征分析及清热化湿凉血解毒法治疗疗效评价[D].北京中医药大学
[23]毛德文.肝衰竭毒邪病因学说辨析[J].中医药导报,2007,13(1)：8-11
[24]陈洁真,郑民安,蒋俊民.健脾解毒化瘀法治疗慢性重型肝炎经验[J].中医研究,2009,22(10)：50-51
[25]朱文芳,谌宁生.谌宁生教授治疗重型肝炎的经验[J].中西医结合肝病杂志,2009.19(6)：362-363
[26]刘友章,王昌俊.重型肝炎中医治疗思路与方法[J].中医药通报,2005,4(4)：17-21
[27]谌宁生,孙克伟.重型肝炎从快速截断论治[J].新中医,2001,33(1)：3-4.
[28]喻洪伟,杨志超.清热利湿活血解毒法为主治疗重型肝炎疗效观察[J].辽宁中医杂志,2003,30(5)：365
[29]周仲瑛.重型肝炎辨治述要[J].新中医,2002,34(3)：3-6
[30]田洪,潘善,庆陈子.急性肝损伤动物模型的建立.中国药师.2009,12(4)：449-450
[31]BergerML,BhattH,CombesB,etal-CC14-inducedtoxicity in isolated hepatocytes[J].Hepatology1986 (6):36-45
[32]DeckerK,KepplerD·Galactosamine induced liver in-jury[J].ProgLiverDis, 1972(4):183-199
[33]刘建文.药理试验方法学[M].北京：化学工业出版社.2004：168
[34]尹常健.肝病用药十讲,中国中医药出版社,1998,(1)：280
[35]尹常健.肝病用药十讲,中国中医药出版社,1998,(1)：203
[36]张廷模.临床中药学[M].北京：中国中医药出版社.2004年8月第一版
[37]崔兴日,南极星,吕慧子,等.党参提取物对急性肝损伤小鼠肝脏的保护作用[J].延边大学医学学报.2004,27(4)：262-264
[38]余永邦,秦民坚,余国奠.太子参化学成分、药理作用及质量评价研究进展[.J].中国野生植物资源,2003(4)：1-3
[39]张振明,许爱霞,葛斌,等.太子参水提物的抗氧化活性[J].中国医院药学杂志.2006,26(2)：147-149
[40]张振明,许爱霞,葛斌,等.太子参醇提物对大鼠组织和红细胞的抗氧化活性[J].第四军医大学学报.2005,26(22)：2062-2064
[41]贾树强,王振勇,刘建柱,等.黄芪对四氯化碳致犬急性肝损伤模型抗氧化指标的影响[J].肝脏,2008,13(2)：144-145
[42]李鸿晟.黄芪辅助治疗肝硬化腹水疗效观察[J].中国中医药咨讯,2011,3(17),212
[43]文敏,李雪,付守廷.黄芩苷药理作用研究新进展[J].沈阳药科大学学报2008,25(2)：158-161
[44]张喜平,田华,程琪辉.黄芩苷的药理作用研究现状[J].中国药理学通报.2003,19(11)：1212-1214
[45]宋成岩,刘宇,朴锦花,等.黄芩抗氧化化学成分的研究[J].时珍国医国药.2007,18(4)：856-857
[46]张永镀,周芳燕,徐辉碧.黄芩甙的抗氧化作用[J].华中理工大学学报.1999,27(4)：110-112
[47]李正禄,孟璐,张学武.黄芩苷对小鼠急性肝损伤的保护作用[J].时珍国医国药,2009,20(11)：2752-2753
[48]Nan JX.Scutellaria baicalensis inhibits liver fibrosis induced by bile duct ligation or carbon tetrachloride in rats [J].J Pharm Pharmacol,2002.54:555
[49]Tomoo I.Strong antiproliferative effects of baicalein in cultured rat hepatic stellate cells[J].Eur J Pharmocol.1999,378:129
[50]Kayano K.Inhibitory effects of the herbal medicine Shosaiko-to (TJ-9) on cell proliferation and procollagen gene expressions in cultured rat hepatic stellate cells [J]. J Hepatol,1998,29:642
[51]卢春凤,王丽敏,陈廷玉.黄芩素和黄芩苷对四氯化碳所致肝脏拟伤大鼠转氨酶的影响[J].黑龙江医药科学,2003,26(4)：50
[52]廖晖,王慧梅,王春莲,等.干姜擦剂治疗手足皲裂70例[J].中国中西医结合杂志.2001,21(6)：469
[53]李素婷,石艳华,杨鹤梅,等.黄芩茎叶总黄酮对肝脏MDA生成的影响[J].中国中医药信息杂志,2001,8(6)：23-24
[54]姜英子,金将杰,金成赞,等,黄芩苷对小鼠急性肝损伤的保护作用[J].延边大学医学学报,2003,26(4)：255-257
[55]刘思纯,马博.甘草酸二铵治疗急性药物性肝损伤的疗效观察[J].中国处方药,2006,10(55)：62-64
[56]刘协,顾呈华,胡启之,等.甘草甜素脂质体对小鼠急性酒精性肝损伤的保护作用[J].中国临床康复,2004,8(36)：8260-8261
[57]唐慧,周雯,李慧.茵陈蒿油对小鼠急性酒精性肝损伤的作用[J].中国卫生检验杂志,2008,18(9)：1498-1500
[58]齐彦,郭丽新,周迎春等.五味子对四氯化碳所致小鼠急性肝损伤的作用研究[J].中医药学报,2009,37(4)：26-27
[59]刘丽芳.五味子药理作用研究[J].中国社区医师(综合版),2006,8(18)：13
[60]刘丹,汤海峰,张三奇等.虎杖浓缩片对小鼠实验性肝损伤的保护作用(J].时珍国医国药,2007。18(12)：3034.3035.40-42
[61]鲍红月,陈子越,杨波.虎杖提取物对小鼠急性肝损伤的保护作用[J].海峡药学,2011,23(7)
[62]鲍琛.虎杖提取物对CCl1诱导的小鼠急性肝损伤的保护作用[J].海峡药 学,2010,22(6)36-38
[63]黄建荣,刘咏海,喻志标.白花蛇舌草化学成分和药理活性研究进展[J].中成药.2005,27(11)：1329-1330
[64]吴琼.白花蛇舌草的临床应用概况[J].中药材.2000,23(10)：654-6,57
[65]于新,杜志坚,陈悦娇,等.白花蛇舌草提取物抗氧化作用的研究[J].食品与发酵工业.2002,28(3)：10-12
[66]高超,刘颖,蔡晓敏.白花蛇舌草对正常器官氧化损伤防护效应的实验研究[J].徐州医学院学报.2007,27(5)：294-296
[67]张霞,李胜星.女贞子提取物预防四氯化碳所致小鼠急性肝损伤的实验研究[J].中国实用医刊,2008,35(16)：17-18
[68]胡慧娟,杭秉茜,刘勇.墨早莲对免疫系统的影响[J].中国药科大学学报.1992,23(1)：55
[69]韩英,夏超,陈小媛.墨早莲化学成分及药理活性的初步研究[J].中国中药杂志.1998,23(11)：680-681
[70]徐汝明,邓克敏,陆阳.墨早莲活性成分对刀豆蛋白A诱导的小鼠肝损伤的作用[J].上海交通大学学报(医学版).2010,30(1)：50-54
[71]王金梅,许启泰,康文艺.连翘化学成分及药理研究进展[J].天然产物研究与开发[J].2007,19：153-157
[72]朴香兰,吴倩,田燕泽.连翘的抗氧化成分研究[J].时珍国医国药.2010,21(6)：1307-1309
[73]杨建雄,杨晨,邱娟.连翘叶中苷类成分工的体外抗氧化作用研究[J].陕西师范大学学报(自然科学报).2006,34(4)：79-82
[74]陈向荣,陆京伯,石汉平.丹参的药理作用研究新进展[J].中国医院药学杂志[J].2001,21(1)：44-45
[75]吴百灵.丹参对CC14所致急性肝损伤保护作用的研究[J].中医药学刊.2002,20(3)：363-364
[76]郑晓宾,韩德五,许瑞玲,等.丹参防治实验性急性肝损伤机制的研究[J].中国免疫学杂志,1997,13：157-158
[77]覃筱燕,唐丽,严莉.T淋巴细胞亚群在丹参酮ⅡA抗免疫性肝损伤中的作用[J] .辽宁中医杂志,2010,37(1)：6-8
[78]刘四海,戴华.苦参素的药理作用与临床应用[J].中药药理与临床.2007,23(5)：245-246
[79]宋宝君.苦参素治疗慢性乙型肝炎的疗效观察[J].世界中西医结合杂志.2009,4(4).288-289
[80]许红兰.苦参的药理研究发展[J].现代医药卫生.2008,24(20)：3306
[81]周维书.现代医院药学[J].北京：中国医药科技出版社.1993：580
[82]Lorraine I, Mckay, John A. Molecular Control of Immune/infiammatory Response:Interactions Between Nuclear factor-K B and steroid Receptor-Signaling Pathways [J]. Endocrine Reviews.2004:435-459
[83]Nawata R, Yujiri T. Nakamura Y. et al. MEK kinase 1 mediates the anti apoptotic effect of the Bcr-Abi one ogene through NF-κB activation[J]. On-cogene. 2003,22(49):7774-7780.
[84]Garg A. Aggawal BB. Nuclear transcription factor-K B as a target for cancer drug development [J]. Leukemia,2002.16:1053-1068
[85]Andrew B, Luke AJ. Oxidative stress and nuclear factor-KB activation[J].Biol Pharmacologu,2000,59(1):13-23
[86]Ye J. Ding M, Zhang X, et al. On the role of hydroxyl radical and the effect of tetrandrine on nuclear factor-KB activation by phorbol 12-myristate 13-acetate[J]. Ann Clin Lab Sci,2000,30(1):65-71
[87]Yamazaki S, Muta T, Takeshige K. Anovel IkappaB protein, Ikap paB-zeta.nduced by proinflammatory stimuli, negatively regulates nuclear factor-kappa B in the nuclei [J]. J Biol Chem,2001,276 (29):27657-27667
[88]Fukman K. Marubayashi S, Okada K. et al. Efect of lazaroid U-74389G and methylprednisolone on endotoxm-induced shock in mice[J]. Surgery,1999,125(4): 421-430
[89]Fox ES, Kim JC. Tracy TR. NF-kappaB activation and modulation in hepatic macrophages during cholestatic injury[J]. J Surg Res,1997.72(2):129-134
[90]Nanji AA. Jokelaine K. Rahemtulla a, et al. Activation of nuclear factor kappa B and cytokirie imbalance in experimental alcoholic liver disease in the rats[J]. Hepatology,1999; 30(4):934-943
[91]Zwacka RM, Zhou W, Zhang, et al. Redox gene therapy for ischemia/reperfusion injury of the liver reduce API and NF-kappa B activation[J]. Nat Ned,1998; 4(6): 698-704
[92]Mirza A, Liu SL, Frizell E, et al. A role for tissue transglutaminase in hepatic Injury and fibrogenesis, and its regulation by NF-kappa B[J]. Am J Physiol,1997; 272(2):G281-288
[93]Kono H. Wheeler MD, Rusyn. et al. Gender differences in early alchohol-induced liver injury:a role of CD14, NF-kappa B, and TNF-alpha[J]. Am J Physiol Gastrointest Liver Physiol,2000; 278(4):652-661
[94]Beg AA, Sha WC, Bronson RT, et al. Embryonic let hality and liver degeneration in mice lacking the Rel A component of NF-kappa B[J].Nature,1995,376 (6536):167-170
[95]Feng D. Mei Y, Wang Y, et al Tetrandine protects mice from concanavalin A-induced hepatitis through inhibiting NF-kappa B activation[J].Immunol Lett,2008.121 (2):127-133
[96]Chung C,Park SG,Park YM,et al.Interferon-gamma sensitizes hepatitis B virus-expressing hepatocarcinoma cells to 5-fluorouracil through inhibition of hepatitis B virus-mediated nuclear factor-kappa B activition[J].Cancer sci,2007,98(11):1758-1766
[97]Ke B,Shen XD.Tsuchihashi S.et al.Viral interleukin-10 gene transfer prevents liver ischemia-reperfusion injury:Toll-like receptor-4 and heme oxygenase-1 signaling in innate and adaptive immunity [J]. Hum Gene Ther,2007,18(4):355-366
[98]Kuhnel F, Zender L, Paul Y, et al. NF-κB mediates apoptosist hrough transcriptional activation of Fas (CD95) in adenoviral hepatitis[J]. J Biol Chem, 2000.275 (9):6421-6427
[99]Gil J, Alcami J, Esteban M. Induction of apoptosis by double Stranded-RNA-dependent protein kinase (PKR) involves the a subunit of eukaryotic translation initiation factor and NF-κB[J]. Mol Cell Bio,1999,19 (7):4653-4663
[100]Oakley F, Meso M, Iredale J P., et al. Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis[J]. Gast roenterology,2005.128 (1):108-120
[101]Subram an iam S, Stansberg C, Cunningham C. The interleukin 1 recepto r family [J].Dev Comp Immunol.2004,28(5):415-428
[102]Yang J, Shi D, Yang D, et al. Interleukin-6 alters the cellular responsive ness to clopidogre, irinotecan. and oseltamivir by suppressing the expression of carboxylesterasesHCE1 andHCE2 molecular pharmacology[J].Mol Pharmaco,20 07,72(3):686-694
[103]Lemmers A, Gustot T, Durnez A. et al. An inhibitor of interleukin-6 tran s-signalling, sg p130, contributes to impaired acute phase response in human c hronic liver disease [J]. Clin Exp Immunol,2009,156(3):518-527
[104]Ilmakunnas M, H ckerstedtK. Makisalo H, etal. Hepatic IL-8 release duri ng graft procurement is associated with impaired graft function after human liv er transplantation [J]. Clin Transplant,2009,17(4):96-97
[105]Joshi-Barve S, Barve SS, Amancherla K, et al. Palmitic acid induces pro duction of pro inflammatory cytokine interleukin-8 from hepatocytes[J].Hepatolo gy,2007,46(3):823-830
[1]Viatour P,Merville MP,Bours V,et al.Phosphorylation of NF-kappa B and I kappa B protein:implications in cancer and inflammation[J]. Trends Biochem Sci,2005,30(1):43
[2]吴礼国,欧阳钦,叶华田.Rel/NF-κB信号传导通路与UC生物治疗策略的关系[J].国外医学·消化系统疾病分册,2004,24(6)：335
[3]郝筱倩,董蕾.细胞因子的表达和NF-κB的激活在UC中作用机制的探讨[J].胃肠病学,2005,1(6)：1
[4]舒德忠,周岐新.炎症性肠病相关受体蛋白和转录调节因子的研究[J].生理科学进展,2005,36(3)：269
[5]梁道兰,张良清,徐军发,等.腺苷预处理对缺血再灌注心肌细胞凋亡及NF-κB表达的影响[J].广东医学,2004,25(2)：140
[6]Aquila S,Weng ZY,Zeng YQ,et al.Inhibition of NF-kap-paB activation and iNOS induction by ent-kaurane diterpe-noids in LPS-stimulated RAW264.7 murine macrophages[J].JNat Prod,2009,72(7):1269
[7]顾培青,沈洪,刘丽.清肠化湿方对溃疡性结肠炎模型大鼠结肠TLR-4、NF-κBp65蛋白表达的影响.中国中医急症,2010,19(1)：99-101
[8]陈名涛,李晨.清肠汤对大肠湿热型溃疡性结肠炎大鼠组NF-κB p65及TLR4的影响.湖北中医学院学报,2009,11(5)：12-14
[9]张静喆,梁晓强,顾宏刚,等.清胆胶囊对胆固醇结石小鼠肝脏中PPAR-γ、CYP7A1及NF-κB表达的影响.中国中西医结合消化杂志,2010,18(4)：254-257
[10]黄作义,许志刚,吴成吉,等.远志对Aβ25-35诱导AD模型大鼠海马区NF-κB活化研究.黑龙江医药科学,2010,33(2)：6-7
[11]荣英蕊,刘建平,陈建权.泄浊解毒方对溃疡性结肠炎大鼠结肠组织NF-κBp65及ICAM-1表达的影响.上海中医药杂志,2010,44(3)：63-66
[12]李春杰,魏品康,余柏林等。消痰散结方干预对胃癌组织核转录因子NF-κBP65蛋白表达影响的研究.中国临床保健杂志,2010,13(1)：62-64
[13]周必发,张莹雯.当归补血汤对高糖条件下系膜细胞增殖及TGF-β1mRNA和NF-κB表达的影响.中华中医药杂志,2010,25(6)：833-838
[14]梁丽,范恒,段雪云等.β2AR、β-arrestin2、NF-κBp65在溃疡性结肠炎大鼠中的表达及乌梅丸的干预作用.世界华人消化杂志,2010,18(16)：1650-1655
[15]张超贤,郭晓凤,秦咏梅.黄芪注射液对急性胰腺炎大鼠NF-κB活性、NF-κB及TNF-αmRNA表达的影响.世界华人消化杂志,2010 18(10)：1051-1055
[16]许金华,秦振启,周钰娟等.金樱子对糖尿病大鼠肝MCP-1、TNF-α和NF-κB表达的影响.南华大学学报·医学版,201(),38(3)：318-321
[17]宝东艳,王爱梅,李伟红.丹参对庆大霉素耳中毒豚鼠耳蜗NF-κB舌性的影响.中国现代医学杂志,2009,19(7)：2601-2606
[18]侯延庆,王自能,王冬菊.复方丹参注射液对滋养细胞JEG-3氧化应激中核因 子-κB表达的影响.中国中医急症.2010,19(5)：861-863
[19]李绚,阎蓉华,彭谨.黄芩苷通过降低高脂血症大鼠肾小球核因子κB及可溶性单核细胞趋化蛋白表达抑制肾脏炎性反应.中国动脉硬化杂志.2010,18(8)：611-613
[20]刘庆生,蔡丹莉,陈芝芸等.三七对酒精性肝病大鼠肝组织NF-κB、c-Jun表达的影响.中国药学杂志.2010,45(18)：1384-1388
[21]郑子春,沈洪,朱萱萱.黄柏、地榆、白及对溃疡性结肠炎大鼠组织中NF-κB和细胞因子表达的影响.中国中医急症,2010,19(3)：469-472
[22]李均,李莹莹,曹轶璇.虎杖对肾缺血-再灌注损伤大鼠肾组织内皮素和核转录因子的影响.中药材,2010,33(9)：1469-1472
[23]吴艳霞,付雷,黄浩.大黄素对心肌梗死后小鼠心肌组织TNF-α、IL-10基因表达和NF-κB活性的影响.中国临床药理学与治疗学,2010,15(3)：287-291
[24]杨群华,唐省三.灯盏花素对大鼠脑缺血-再灌注后脑内NF-κB表达的抑制作用.中药材.2010,33(7)：1154-1156
[25]赵国安,齐三利,汤汝佳.灯盏花素联合预适应对兔缺血再灌注心肌肿瘤坏死因子α、核因子-κB的影响.临床心血管杂志,2010,26(8)：631-634
[26]汪海东,夏世金,陈颂春.淫羊藿苷经NF-κB信号通路干预大鼠免疫衰老的作用及机制.中国老年学杂志.2010,30：2938-2941
[27]江小萍,李海全,潘少霞.三七总皂苷对缺氧再给氧血管内皮细胞NF-κB及ICAM-1.表达的影响.中西医结合心脑血管病杂志,2010,8(9)：1086-1088
[28]刁波,唐瑛朱,以良.刺五加多糖对HZOZ损伤的海马神经元表达NF—κB的影响.中国临床神经外科杂志,2010,15(6)：350-352
[29]任丹虹,方堃,应可净.穿心莲内酯对人肺腺癌A549细胞NF-κB通路的调控作用.中国药理学与毒理学杂志.2010,24(2)：106-110
[30]崔秀玲,工远征,刘晓健.葛根素对糖尿病大鼠肾脏NF-κB65、TNF-α表达的影响.解放军医学杂志,2010,35(6)：679-672
[31]李楠,黄秀蓉,邓小红.葛根素注射液对大鼠光损伤视网膜中NF-κB表达的影响.山西中医学院学报,2010,11(2)：18-20
[2]中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南[J].中华传染病杂志,2006,24(6)：422-425
[3]中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南[J].国际流行病学传染病学杂志,2006,33(4)：217-221
[4]郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社,2002.143-151
[5]Jadad AR, Moore A, Carroll D, etal. Assessing the quality of reports of randomized clinical trials:Is blinding necessary[J].Control Clin TriMs,1996,17:1-12
[6]黄裕红,谌宁生,阳航等.解毒化瘀汤联合中药保留灌肠治疗肝衰竭临床观察[.J].中国中医急证,2007,16(11)：1336-1337
[7]黄裕红,谌宁生,肖俊.中西医结合治疗肝衰竭36例[J].中医研究,2007,20(9)：24-25
[8]谢冬梅,何俊毅姚,立红等.肝衰合剂保留灌肠治疗肝衰竭21例临床观察[J].浙江中医杂志,2008,43(1)：34-35
[9]李建阳,张庭澍,罗蓬等.加味大承气汤灌肠治疗肝衰竭102例[J].陕西中医,2008,29(12)：1639-1640
[10]徐霞,陈飞,谢冬梅.大黄赤芍汤保留灌肠治疗肝衰竭的效果观察[J].护理与康复,2009,8(7)：616-617
[11]刘炜.中西医结合治疗重型肝炎湿热内蕴证疗效观察[J].湖北中医杂志,2009,31(1)：20-21
[12]孙元鹏.中西医结合治疗重症肝炎临床疗效观察[J].山西中医,2009,25(9)：29-30
[13]张鹏程.茵陈五苓散加减治疗肝衰竭的理论与临床研究[D].南京中医药大学
[14]毛建华.加味茵陈蒿汤合加减大承气汤治疗慢性重症肝炎临床疗效观察.医 学信息.2010,7：1954-1955
[15]刘政芳,潘晨,张元芬等.中西医结合治疗慢性乙型肝炎肝衰竭的临床研究.传染病信息,2010,23(5)：287-290
[16]陈全超.中西医结合治疗重症肝炎30例临床分析.亚太传统医药,2010,6(7)：42-43
[17]陈飞,徐洁,谢冬梅等.二黄解毒汤保留灌肠治疗肝功能衰竭的疗效观察及护理[J].海峡药学,2010,22(2)：121-123
[18]谢冬梅,程志文,何俊毅.肝病8号方灌肠治疗肝衰竭59例[J].江西中医药,2010,41(328)：31-32
[19]胡建华,钱英,姚乃礼.“截断逆挽法”治疗慢性乙型重型肝炎临床疗效观察[J].中西医结合肝病杂志,2010,20(4)：200-204
[20]徒康宛.清热解毒-活血化瘀-益气养阴法治疗肝衰竭内毒素血症的研究[D].南京中医药大学
[21]张强.79例亚急性肝衰竭患者临床特征分析及中西医结合治疗疗效评价[D].北京中医药大学
[22]沈云.慢加急性肝衰竭临床特征分析及清热化湿凉血解毒法治疗疗效评价[D].北京中医药大学
[23]毛德文.肝衰竭毒邪病因学说辨析[J].中医药导报,2007,13(1)：8-11
[24]陈洁真,郑民安,蒋俊民.健脾解毒化瘀法治疗慢性重型肝炎经验[J].中医研究,2009,22(10)：50-51
[25]朱文芳,谌宁生.谌宁生教授治疗重型肝炎的经验[J].中西医结合肝病杂志,2009.19(6)：362-363
[26]刘友章,王昌俊.重型肝炎中医治疗思路与方法[J].中医药通报,2005,4(4)：17-21
[27]谌宁生,孙克伟.重型肝炎从快速截断论治[J].新中医,2001,33(1)：3-4.
[28]喻洪伟,杨志超.清热利湿活血解毒法为主治疗重型肝炎疗效观察[J].辽宁中医杂志,2003,30(5)：365
[29]周仲瑛.重型肝炎辨治述要[J].新中医,2002,34(3)：3-6
[30]田洪,潘善,庆陈子.急性肝损伤动物模型的建立.中国药师.2009,12(4)：449-450
[31]BergerML,BhattH,CombesB,etal-CC14-inducedtoxicity in isolated hepatocytes[J].Hepatology1986 (6):36-45
[32]DeckerK,KepplerD·Galactosamine induced liver in-jury[J].ProgLiverDis, 1972(4):183-199
[33]刘建文.药理试验方法学[M].北京：化学工业出版社.2004：168
[34]尹常健.肝病用药十讲,中国中医药出版社,1998,(1)：280
[35]尹常健.肝病用药十讲,中国中医药出版社,1998,(1)：203
[36]张廷模.临床中药学[M].北京：中国中医药出版社.2004年8月第一版
[37]崔兴日,南极星,吕慧子,等.党参提取物对急性肝损伤小鼠肝脏的保护作用[J].延边大学医学学报.2004,27(4)：262-264
[38]余永邦,秦民坚,余国奠.太子参化学成分、药理作用及质量评价研究进展[.J].中国野生植物资源,2003(4)：1-3
[39]张振明,许爱霞,葛斌,等.太子参水提物的抗氧化活性[J].中国医院药学杂志.2006,26(2)：147-149
[40]张振明,许爱霞,葛斌,等.太子参醇提物对大鼠组织和红细胞的抗氧化活性[J].第四军医大学学报.2005,26(22)：2062-2064
[41]贾树强,王振勇,刘建柱,等.黄芪对四氯化碳致犬急性肝损伤模型抗氧化指标的影响[J].肝脏,2008,13(2)：144-145
[42]李鸿晟.黄芪辅助治疗肝硬化腹水疗效观察[J].中国中医药咨讯,2011,3(17),212
[43]文敏,李雪,付守廷.黄芩苷药理作用研究新进展[J].沈阳药科大学学报2008,25(2)：158-161
[44]张喜平,田华,程琪辉.黄芩苷的药理作用研究现状[J].中国药理学通报.2003,19(11)：1212-1214
[45]宋成岩,刘宇,朴锦花,等.黄芩抗氧化化学成分的研究[J].时珍国医国药.2007,18(4)：856-857
[46]张永镀,周芳燕,徐辉碧.黄芩甙的抗氧化作用[J].华中理工大学学报.1999,27(4)：110-112
[47]李正禄,孟璐,张学武.黄芩苷对小鼠急性肝损伤的保护作用[J].时珍国医国药,2009,20(11)：2752-2753
[48]Nan JX.Scutellaria baicalensis inhibits liver fibrosis induced by bile duct ligation or carbon tetrachloride in rats [J].J Pharm Pharmacol,2002.54:555
[49]Tomoo I.Strong antiproliferative effects of baicalein in cultured rat hepatic stellate cells[J].Eur J Pharmocol.1999,378:129
[50]Kayano K.Inhibitory effects of the herbal medicine Shosaiko-to (TJ-9) on cell proliferation and procollagen gene expressions in cultured rat hepatic stellate cells [J]. J Hepatol,1998,29:642
[51]卢春凤,王丽敏,陈廷玉.黄芩素和黄芩苷对四氯化碳所致肝脏拟伤大鼠转氨酶的影响[J].黑龙江医药科学,2003,26(4)：50
[52]廖晖,王慧梅,王春莲,等.干姜擦剂治疗手足皲裂70例[J].中国中西医结合杂志.2001,21(6)：469
[53]李素婷,石艳华,杨鹤梅,等.黄芩茎叶总黄酮对肝脏MDA生成的影响[J].中国中医药信息杂志,2001,8(6)：23-24
[54]姜英子,金将杰,金成赞,等,黄芩苷对小鼠急性肝损伤的保护作用[J].延边大学医学学报,2003,26(4)：255-257
[55]刘思纯,马博.甘草酸二铵治疗急性药物性肝损伤的疗效观察[J].中国处方药,2006,10(55)：62-64
[56]刘协,顾呈华,胡启之,等.甘草甜素脂质体对小鼠急性酒精性肝损伤的保护作用[J].中国临床康复,2004,8(36)：8260-8261
[57]唐慧,周雯,李慧.茵陈蒿油对小鼠急性酒精性肝损伤的作用[J].中国卫生检验杂志,2008,18(9)：1498-1500
[58]齐彦,郭丽新,周迎春等.五味子对四氯化碳所致小鼠急性肝损伤的作用研究[J].中医药学报,2009,37(4)：26-27
[59]刘丽芳.五味子药理作用研究[J].中国社区医师(综合版),2006,8(18)：13
[60]刘丹,汤海峰,张三奇等.虎杖浓缩片对小鼠实验性肝损伤的保护作用(J].时珍国医国药,2007。18(12)：3034.3035.40-42
[61]鲍红月,陈子越,杨波.虎杖提取物对小鼠急性肝损伤的保护作用[J].海峡药学,2011,23(7)
[62]鲍琛.虎杖提取物对CCl1诱导的小鼠急性肝损伤的保护作用[J].海峡药 学,2010,22(6)36-38
[63]黄建荣,刘咏海,喻志标.白花蛇舌草化学成分和药理活性研究进展[J].中成药.2005,27(11)：1329-1330
[64]吴琼.白花蛇舌草的临床应用概况[J].中药材.2000,23(10)：654-6,57
[65]于新,杜志坚,陈悦娇,等.白花蛇舌草提取物抗氧化作用的研究[J].食品与发酵工业.2002,28(3)：10-12
[66]高超,刘颖,蔡晓敏.白花蛇舌草对正常器官氧化损伤防护效应的实验研究[J].徐州医学院学报.2007,27(5)：294-296
[67]张霞,李胜星.女贞子提取物预防四氯化碳所致小鼠急性肝损伤的实验研究[J].中国实用医刊,2008,35(16)：17-18
[68]胡慧娟,杭秉茜,刘勇.墨早莲对免疫系统的影响[J].中国药科大学学报.1992,23(1)：55
[69]韩英,夏超,陈小媛.墨早莲化学成分及药理活性的初步研究[J].中国中药杂志.1998,23(11)：680-681
[70]徐汝明,邓克敏,陆阳.墨早莲活性成分对刀豆蛋白A诱导的小鼠肝损伤的作用[J].上海交通大学学报(医学版).2010,30(1)：50-54
[71]王金梅,许启泰,康文艺.连翘化学成分及药理研究进展[J].天然产物研究与开发[J].2007,19：153-157
[72]朴香兰,吴倩,田燕泽.连翘的抗氧化成分研究[J].时珍国医国药.2010,21(6)：1307-1309
[73]杨建雄,杨晨,邱娟.连翘叶中苷类成分工的体外抗氧化作用研究[J].陕西师范大学学报(自然科学报).2006,34(4)：79-82
[74]陈向荣,陆京伯,石汉平.丹参的药理作用研究新进展[J].中国医院药学杂志[J].2001,21(1)：44-45
[75]吴百灵.丹参对CC14所致急性肝损伤保护作用的研究[J].中医药学刊.2002,20(3)：363-364
[76]郑晓宾,韩德五,许瑞玲,等.丹参防治实验性急性肝损伤机制的研究[J].中国免疫学杂志,1997,13：157-158
[77]覃筱燕,唐丽,严莉.T淋巴细胞亚群在丹参酮ⅡA抗免疫性肝损伤中的作用[J] .辽宁中医杂志,2010,37(1)：6-8
[78]刘四海,戴华.苦参素的药理作用与临床应用[J].中药药理与临床.2007,23(5)：245-246
[79]宋宝君.苦参素治疗慢性乙型肝炎的疗效观察[J].世界中西医结合杂志.2009,4(4).288-289
[80]许红兰.苦参的药理研究发展[J].现代医药卫生.2008,24(20)：3306
[81]周维书.现代医院药学[J].北京：中国医药科技出版社.1993：580
[82]Lorraine I, Mckay, John A. Molecular Control of Immune/infiammatory Response:Interactions Between Nuclear factor-K B and steroid Receptor-Signaling Pathways [J]. Endocrine Reviews.2004:435-459
[83]Nawata R, Yujiri T. Nakamura Y. et al. MEK kinase 1 mediates the anti apoptotic effect of the Bcr-Abi one ogene through NF-κB activation[J]. On-cogene. 2003,22(49):7774-7780.
[84]Garg A. Aggawal BB. Nuclear transcription factor-K B as a target for cancer drug development [J]. Leukemia,2002.16:1053-1068
[85]Andrew B, Luke AJ. Oxidative stress and nuclear factor-KB activation[J].Biol Pharmacologu,2000,59(1):13-23
[86]Ye J. Ding M, Zhang X, et al. On the role of hydroxyl radical and the effect of tetrandrine on nuclear factor-KB activation by phorbol 12-myristate 13-acetate[J]. Ann Clin Lab Sci,2000,30(1):65-71
[87]Yamazaki S, Muta T, Takeshige K. Anovel IkappaB protein, Ikap paB-zeta.nduced by proinflammatory stimuli, negatively regulates nuclear factor-kappa B in the nuclei [J]. J Biol Chem,2001,276 (29):27657-27667
[88]Fukman K. Marubayashi S, Okada K. et al. Efect of lazaroid U-74389G and methylprednisolone on endotoxm-induced shock in mice[J]. Surgery,1999,125(4): 421-430
[89]Fox ES, Kim JC. Tracy TR. NF-kappaB activation and modulation in hepatic macrophages during cholestatic injury[J]. J Surg Res,1997.72(2):129-134
[90]Nanji AA. Jokelaine K. Rahemtulla a, et al. Activation of nuclear factor kappa B and cytokirie imbalance in experimental alcoholic liver disease in the rats[J]. Hepatology,1999; 30(4):934-943
[91]Zwacka RM, Zhou W, Zhang, et al. Redox gene therapy for ischemia/reperfusion injury of the liver reduce API and NF-kappa B activation[J]. Nat Ned,1998; 4(6): 698-704
[92]Mirza A, Liu SL, Frizell E, et al. A role for tissue transglutaminase in hepatic Injury and fibrogenesis, and its regulation by NF-kappa B[J]. Am J Physiol,1997; 272(2):G281-288
[93]Kono H. Wheeler MD, Rusyn. et al. Gender differences in early alchohol-induced liver injury:a role of CD14, NF-kappa B, and TNF-alpha[J]. Am J Physiol Gastrointest Liver Physiol,2000; 278(4):652-661
[94]Beg AA, Sha WC, Bronson RT, et al. Embryonic let hality and liver degeneration in mice lacking the Rel A component of NF-kappa B[J].Nature,1995,376 (6536):167-170
[95]Feng D. Mei Y, Wang Y, et al Tetrandine protects mice from concanavalin A-induced hepatitis through inhibiting NF-kappa B activation[J].Immunol Lett,2008.121 (2):127-133
[96]Chung C,Park SG,Park YM,et al.Interferon-gamma sensitizes hepatitis B virus-expressing hepatocarcinoma cells to 5-fluorouracil through inhibition of hepatitis B virus-mediated nuclear factor-kappa B activition[J].Cancer sci,2007,98(11):1758-1766
[97]Ke B,Shen XD.Tsuchihashi S.et al.Viral interleukin-10 gene transfer prevents liver ischemia-reperfusion injury:Toll-like receptor-4 and heme oxygenase-1 signaling in innate and adaptive immunity [J]. Hum Gene Ther,2007,18(4):355-366
[98]Kuhnel F, Zender L, Paul Y, et al. NF-κB mediates apoptosist hrough transcriptional activation of Fas (CD95) in adenoviral hepatitis[J]. J Biol Chem, 2000.275 (9):6421-6427
[99]Gil J, Alcami J, Esteban M. Induction of apoptosis by double Stranded-RNA-dependent protein kinase (PKR) involves the a subunit of eukaryotic translation initiation factor and NF-κB[J]. Mol Cell Bio,1999,19 (7):4653-4663
[100]Oakley F, Meso M, Iredale J P., et al. Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis[J]. Gast roenterology,2005.128 (1):108-120
[101]Subram an iam S, Stansberg C, Cunningham C. The interleukin 1 recepto r family [J].Dev Comp Immunol.2004,28(5):415-428
[102]Yang J, Shi D, Yang D, et al. Interleukin-6 alters the cellular responsive ness to clopidogre, irinotecan. and oseltamivir by suppressing the expression of carboxylesterasesHCE1 andHCE2 molecular pharmacology[J].Mol Pharmaco,20 07,72(3):686-694
[103]Lemmers A, Gustot T, Durnez A. et al. An inhibitor of interleukin-6 tran s-signalling, sg p130, contributes to impaired acute phase response in human c hronic liver disease [J]. Clin Exp Immunol,2009,156(3):518-527
[104]Ilmakunnas M, H ckerstedtK. Makisalo H, etal. Hepatic IL-8 release duri ng graft procurement is associated with impaired graft function after human liv er transplantation [J]. Clin Transplant,2009,17(4):96-97
[105]Joshi-Barve S, Barve SS, Amancherla K, et al. Palmitic acid induces pro duction of pro inflammatory cytokine interleukin-8 from hepatocytes[J].Hepatolo gy,2007,46(3):823-830
[1]Viatour P,Merville MP,Bours V,et al.Phosphorylation of NF-kappa B and I kappa B protein:implications in cancer and inflammation[J]. Trends Biochem Sci,2005,30(1):43
[2]吴礼国,欧阳钦,叶华田.Rel/NF-κB信号传导通路与UC生物治疗策略的关系[J].国外医学·消化系统疾病分册,2004,24(6)：335
[3]郝筱倩,董蕾.细胞因子的表达和NF-κB的激活在UC中作用机制的探讨[J].胃肠病学,2005,1(6)：1
[4]舒德忠,周岐新.炎症性肠病相关受体蛋白和转录调节因子的研究[J].生理科学进展,2005,36(3)：269
[5]梁道兰,张良清,徐军发,等.腺苷预处理对缺血再灌注心肌细胞凋亡及NF-κB表达的影响[J].广东医学,2004,25(2)：140
[6]Aquila S,Weng ZY,Zeng YQ,et al.Inhibition of NF-kap-paB activation and iNOS induction by ent-kaurane diterpe-noids in LPS-stimulated RAW264.7 murine macrophages[J].JNat Prod,2009,72(7):1269
[7]顾培青,沈洪,刘丽.清肠化湿方对溃疡性结肠炎模型大鼠结肠TLR-4、NF-κBp65蛋白表达的影响.中国中医急症,2010,19(1)：99-101
[8]陈名涛,李晨.清肠汤对大肠湿热型溃疡性结肠炎大鼠组NF-κB p65及TLR4的影响.湖北中医学院学报,2009,11(5)：12-14
[9]张静喆,梁晓强,顾宏刚,等.清胆胶囊对胆固醇结石小鼠肝脏中PPAR-γ、CYP7A1及NF-κB表达的影响.中国中西医结合消化杂志,2010,18(4)：254-257
[10]黄作义,许志刚,吴成吉,等.远志对Aβ25-35诱导AD模型大鼠海马区NF-κB活化研究.黑龙江医药科学,2010,33(2)：6-7
[11]荣英蕊,刘建平,陈建权.泄浊解毒方对溃疡性结肠炎大鼠结肠组织NF-κBp65及ICAM-1表达的影响.上海中医药杂志,2010,44(3)：63-66
[12]李春杰,魏品康,余柏林等。消痰散结方干预对胃癌组织核转录因子NF-κBP65蛋白表达影响的研究.中国临床保健杂志,2010,13(1)：62-64
[13]周必发,张莹雯.当归补血汤对高糖条件下系膜细胞增殖及TGF-β1mRNA和NF-κB表达的影响.中华中医药杂志,2010,25(6)：833-838
[14]梁丽,范恒,段雪云等.β2AR、β-arrestin2、NF-κBp65在溃疡性结肠炎大鼠中的表达及乌梅丸的干预作用.世界华人消化杂志,2010,18(16)：1650-1655
[15]张超贤,郭晓凤,秦咏梅.黄芪注射液对急性胰腺炎大鼠NF-κB活性、NF-κB及TNF-αmRNA表达的影响.世界华人消化杂志,2010 18(10)：1051-1055
[16]许金华,秦振启,周钰娟等.金樱子对糖尿病大鼠肝MCP-1、TNF-α和NF-κB表达的影响.南华大学学报·医学版,201(),38(3)：318-321
[17]宝东艳,王爱梅,李伟红.丹参对庆大霉素耳中毒豚鼠耳蜗NF-κB舌性的影响.中国现代医学杂志,2009,19(7)：2601-2606
[18]侯延庆,王自能,王冬菊.复方丹参注射液对滋养细胞JEG-3氧化应激中核因 子-κB表达的影响.中国中医急症.2010,19(5)：861-863
[19]李绚,阎蓉华,彭谨.黄芩苷通过降低高脂血症大鼠肾小球核因子κB及可溶性单核细胞趋化蛋白表达抑制肾脏炎性反应.中国动脉硬化杂志.2010,18(8)：611-613
[20]刘庆生,蔡丹莉,陈芝芸等.三七对酒精性肝病大鼠肝组织NF-κB、c-Jun表达的影响.中国药学杂志.2010,45(18)：1384-1388
[21]郑子春,沈洪,朱萱萱.黄柏、地榆、白及对溃疡性结肠炎大鼠组织中NF-κB和细胞因子表达的影响.中国中医急症,2010,19(3)：469-472
[22]李均,李莹莹,曹轶璇.虎杖对肾缺血-再灌注损伤大鼠肾组织内皮素和核转录因子的影响.中药材,2010,33(9)：1469-1472
[23]吴艳霞,付雷,黄浩.大黄素对心肌梗死后小鼠心肌组织TNF-α、IL-10基因表达和NF-κB活性的影响.中国临床药理学与治疗学,2010,15(3)：287-291
[24]杨群华,唐省三.灯盏花素对大鼠脑缺血-再灌注后脑内NF-κB表达的抑制作用.中药材.2010,33(7)：1154-1156
[25]赵国安,齐三利,汤汝佳.灯盏花素联合预适应对兔缺血再灌注心肌肿瘤坏死因子α、核因子-κB的影响.临床心血管杂志,2010,26(8)：631-634
[26]汪海东,夏世金,陈颂春.淫羊藿苷经NF-κB信号通路干预大鼠免疫衰老的作用及机制.中国老年学杂志.2010,30：2938-2941
[27]江小萍,李海全,潘少霞.三七总皂苷对缺氧再给氧血管内皮细胞NF-κB及ICAM-1.表达的影响.中西医结合心脑血管病杂志,2010,8(9)：1086-1088
[28]刁波,唐瑛朱,以良.刺五加多糖对HZOZ损伤的海马神经元表达NF—κB的影响.中国临床神经外科杂志,2010,15(6)：350-352
[29]任丹虹,方堃,应可净.穿心莲内酯对人肺腺癌A549细胞NF-κB通路的调控作用.中国药理学与毒理学杂志.2010,24(2)：106-110
[30]崔秀玲,工远征,刘晓健.葛根素对糖尿病大鼠肾脏NF-κB65、TNF-α表达的影响.解放军医学杂志,2010,35(6)：679-672
[31]李楠,黄秀蓉,邓小红.葛根素注射液对大鼠光损伤视网膜中NF-κB表达的影响.山西中医学院学报,2010,11(2)：18-20
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |